<DOC>
	<DOC>NCT02263976</DOC>
	<brief_summary>Main study: To investigate safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of BEA 2180 BR Sub-study; To investigate whether treatment with 36 μg tiotropium bromide is able to protect of methacholine-induced bronchoconstriction compared to baseline (methacholine challenge at screening).</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Methacholine Chloride</mesh_term>
	<criteria>Healthy male volunteers based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12lead ECG, clinical laboratory test No finding deviating from normal and of clinical relevance No evidence of a clinically relevant concomitant disease Age ≥ 30 and Age ≤ 55 years Body Mass Index (BMI) ≥ 18.5 and BMI &lt; 30 kg/m2 Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator (or his deputy) Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than 10 halflives of the respective drug prior to administration or during the trial Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial Participation in another trial with an investigational drug within two months prior to administration or during the trial Alcohol abuse (more than 60 g/day) Drug abuse Blood donation (more than 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within one week prior to administration or during the trial) Any laboratory value outside the reference range of clinical relevance Exclusion criteria specific for this study: Bronchial hyperreactivity as demonstrated by a 45% change of SGaw at or below a cumulative methacholine concentration of 10 mg/mL = 1% Asthma or bronchial hyperreactivity Allergic rhinitis (hay fever) Glaucoma Urinary tract obstruction Epilepsy History of cardiovascular disease History of peptic ulcer disease History of thyroid disease</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>